Brand Name(s): Enablex
CAS nº: 133099-04-4
(dar e fen a sin)
What is Darifencacin?
Darifencacin (darifenacin) is a medication used to treat urinary incontinence.
This medication works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. However, it should not be used in people with urinary retention.
Darifencacin (darifenacin) is sold under the brand name Enablex® by Novartis.
Latest News
Incontinence: Don’t Suffer In Silence
Incontinence affects nearly half of all women at some point in their lives, but it is a problem...
[more]New drug for overactive bladder lacks cognitive side effects
Darifenacin, a selective muscarinic M3 receptor antagonist approved last month for the treatment of...
[more]FDA Approves Enablex (Darifenacin) for Treatment of Overactive Bladder
Novartis Pharmaceuticals Corporation announced that the U.S. Food and Drug Administration (FDA) has...
[more]International Approvals: Canada, EU, Israel, Norway, Iceland
Anagrelide HCl has been approved in the European Union (EU) as a second-line therapy for essential...
[more]Darifenacin substantially improves quality of life for people with overactive bladder symptoms
Darifenacin significantly improves important emotional, physical and social limitations associated...
[more]